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Available online 16 May 2016The application of inhibitors of the Rho kinase pathway (ROCK inhibitors) to the surface of the eye in the form of
eyedrops has beneﬁcial effects which aid the recovery of diseased or injured endothelial cells that line the inner
surface of the cornea. The aim of this study was to test the plausibility of delivering a selective ROCK inhibitor, Y-
27632, to the cornea using a thin polymeric ﬁlm. Mucoadhesive polymeric thin ﬁlms were prepared incorporat-
ing Y-27632 and diffusional release into PBS was determined. Topical ocular delivery from the applied ﬁlm was
investigated using freshly excised porcine eyes and eyedrops of equivalent concentration acted as comparators;
after 24 h the formulationswere removed and the corneas extracted. Drug-loaded thinpolymericﬁlms,with high
clarity and pliability were produced. ROCK inhibitor Y-27632 was weakly retained within the ﬁlm, with release
attaining equilibrium after 1 h. This in turn facilitated its rapid ocular delivery, and an approximately three-fold
greater penetration of Y-27632 into cryoprobe-treated corneas was observed from the thin ﬁlm (p b 0.01) com-
pared to eyedrops. These ﬁndings support the further development of ROCK inhibitor delivery to the cornea via
release from thin mucoadhesive ﬁlms to treat vision loss cause by corneal endothelial dysfunction.









The cornea of the eye, which is just over 0.5 mm thick in humans,
owes its transparency to the characteristic spatial arrangement of its
constituent collagens and other extracellular matrix components
which make up much of its thickness (Knupp et al., 2009; Meek and
Knupp, 2015). Lining the inner surface of the cornea is a single layer of
metabolically active endothelial cells which separate the corneal matrix
from the adjacent aqueous humor and prevent the ingress of ﬂuid into
the cornea (Hodson and Miller, 1976). If the endothelial cell layer is
compromised the cornea swells and becomes oedematous, scatters
light and loses its transparency. This results in severe vision loss and
in most cases the only option is corneal transplant surgery. Typically,
corneal endothelial dysfunction occurs because of an inherited disease
called Fuch's endothelial corneal dystrophy (FECD) inwhich corneal en-
dothelial cells deteriorate or are lost over the years. It can also occur as a
result of accidental damage to the corneal endothelium during cataract
surgery to remove or replace the lens of the eye, and this condition is
often referred to as bullous keratopathy. Either way, the endothelial
cell damage causes cornea to imbibe excess ﬂuid and swell, making
the cornea appear hazy (Fig. 1) clouding vision (Fig. 2) (Heiting, 2015;
Royal National Institute of Blind People, 2015).. This is an open access article underTechniques to treat vision loss caused by corneal endothelial dysfunc-
tion include an anterior corneal micropuncture and laser treatment to
puncture the corneal epithelium. Although these procedures can be effec-
tive they carry a high risk of rejection and sometimes result in complica-
tions including corneal perforation and scarring (Rahman et al., 2008).
But, by far the most common treatment for corneal endothelial dysfunc-
tion is a corneal graft, and the numbers of surgeries performed indicate
the scale of the problem. The prevalence of FECD, generally, is estimated
to be around 4% of individuals over the age of 40, but in inbred American,
Singaporean and Icelandic populations this rises to 22%, 7% and9% respec-
tively (Zoega et al., 2006; Eghrari et al., 2012; Kitagawa et al., 2002).
In terms of drug therapy, the ROCK signaling pathway has received
recent attention in light of the diverse therapeutic potential of changing
cell behaviour in various diseases such as hypertension, vasospasm, and
glaucoma (Arnold et al., 2013); andmore recently FECD (Koizumi et al.,
2013; Okumura et al., 2009, 2011, 2013, 2015; Nakagawa et al., 2015).
ROCK inhibitors are protein serine/threonine kinases with various func-
tions throughout the body (Riento and Ridley, 2003). Out of several dif-
ferent ROCK inhibitors with different therapeutic effects (Liao et al.,
2007; Wang and Chang, 2014), a selective ROCK inhibitor Y-27632
was reported to have promoted the proliferation of corneal endothelial
cells in vitro (Okumura et al., 2009) and the healing of the corneal endo-
thelium in vivo (Okumura et al., 2011). Sufﬁcient corneal endothelial
cell density is crucial for the ionic pump and barrier functions
(Okumura et al., 2013), which in FECDwould lead to an increased over-
all cell size and cell shape alteration, resulting in endothelialthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Corneal haze of Fuchs Dystrophy.
Table 1
Working formulae to produce methylene blue and ROCK inhibitor Y-27632 ﬁlms.
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density to the normal levels and resume the pump and barrier function,
providing a functional recovery of the cornea. Koizumi et al. (2013) re-
ported that some patients with FECD could be treatedwith ROCK inhib-
itor Y-27632 eye drops subsequent to transcorneal freezing to destroy
damaged corneal endothelial cells.
The delivery of drugs to the eye is basically divided into three routes;
topical, systemic and intraocular. The intraocular route involves an injec-
tion into the eye or use of implants, which is surgically fairly invasive,
carries the risk if infection and is seen undesirable by patients. Systemic
delivery is inefﬁcientwith potential unwanted side effects. The topical de-
livery of drugs to the eye is thus judged to be an attractive route. Examples
of topical delivery include the use of eye drop solutions, ointments, sus-
pensions and emulsions. Eye drops arewidely used, but are easilywashed
out by blinking and nasolacrimal drainage; this means that only a small
amount of the applied dose is likely to penetrate the cornea. Ointment,
suspension and emulsion formulations are widely reported to cause ocu-
lar adverse effects, which include irritation and visual disturbance (Patel
et al., 2013). Studies have been carried out on alternative topical ap-
proaches such as theOCUSERT® system, Topical Opthalmic DrugDelivery
Device,medicated contact lenses and intraocular lenses (Morrison, 2015).
However, none of these approaches are available commercially on the
market. In this study, we investigated an alternative approach based
upon drug-eluting thin polymeric muacoadhesive ﬁlms that afﬁx to the
cornea, in an effort to improve the drawbacks of currentmethods. Our ap-
proach could conceivably lead to amore efﬁcacious and user-friendly de-
vice capable of targeted delivery of ROCK inhibitors to attain improved
clinical effect. Such therapy would also minimize wastage of costly
ROCK inhibitor and avoid potential toxicity from dosing other tissues un-
necessarily, in particular the tear duct and nasal cavity. Therefore, the hy-
pothesis of this study is that topical delivery of ROCK inhibitor Y-27632
from thin mucoadhesive ﬁlms is a superior alternative to eye drops for
trans-corneal drug delivery. This study aimed to test the plausibility of
topical delivery to the cornea from polymeric ﬁlms by the fabrication ofFig. 2. The hazy and clouded vision of a Fuchs patient (left) as compared to normal vision.appropriate ﬁlms, determination of drug release and ﬁnally the determi-
nation of trancorneal drug delivery in vitro.
2. Materials and methods
2.1. Materials
ROCK inhibitor Y-27632 dihydrochloride (MW 247.3) was obtained
fromApexBio Technology LLC (Houston, US). Acetonitrile (HPLC grade),
water (HPLC grade) and phosphate buffered saline (PBS) tablets were
obtained from Fisher Scientiﬁc (Loughborough, UK). Methylene blue
(MW 319.9), polyethylene glycol 400 (PEG 400) and triﬂuoroacetic
acid (≥99.0%) were from Sigma-Aldrich Company Ltd. (Poole, UK).
Carbopol 917 (CP) was a gift from Noveon Inc. (Cleveland, U.S.) and
hydroxyproplymethyl cellulose (HPMC) was a gift from Shin-Etsu
Chemical Co. Ltd. (Tokyo, Japan). Porcine eyeballs were obtained from
a local abattoir by blunt dissection, immediately following slaughter.
2.2. Preparation of thin ﬁlms
Ingredients were weighed into a 250 mL conical ﬂask as detailed in
Table 1 to provide a 1% w/v polymeric solution loaded with either 1.7,
5.2 or 10 mg Y-27632·2HCl; the aqueous solubility of Y-27632·2HCl is
reported as 14 mg/mL (Santa Cruz Biotechnology) and that of methy-
lene blue 43.6 mg/L (Pubchem). The mixtures were stirred overnight
on a magnetic stirrer at room temperature. The following day, the mix-
tures were placed in an ultrasonic bath for 2 h to further assist particle
comminution, and to degas the solution. Next, 50 mL of the solutions
were poured into Petri dishes and left to dry in an oven overnight set
at 60 °C. Once completely dry, the clear ﬁlms were carefully removed
from the petri dish and checked for any imperfections – those that
had bubbles or crystals were discarded.
2.3. Diffusional release from thin ﬁlms
Ten 0.5 × 0.5 cm patches were excised from each drug loaded ﬁlm
and each patch was accurately weighed before being immersed in
1 mL of PBS solution in an Eppendorf tube for various durations (10 s,
20 s, 30 s, 1 min, 2 min, 5 min, 30 min, 1 h, 3 h and 6 h). The patches
were then carefully removed from the PBS solutionwith forceps. The re-
maining solutions were transferred to autosampler vials, prior to analy-
sis by HPLC (Section 2.8). The diffusional release was carried out over
the timescale of up to 6 h to broadly simulate an overnight dosageFilm Working formula
Methylene blue HPMC 0.175 g
PEG 400 0.25 g
CP 0.075 g
Methylene blue 0.01 g
DI H2O to 50 mL
ROCK inhibitor Y-27632 10 mg HPMC 0.175 g
PEG 400 0.25 g
CP 0.075 g
Y-27632·2HCl 10 mg
DI H2O to 50 mL
ROCK inhibitor Y-27632 5.2 mg HPMC 0.175 g
PEG 400 0.25 g
CP 0.075 g
Y-27632·2HCl 5.2 mg
DI H2O to 50 mL
ROCK inhibitor Y-27632 1.7 mg HPMC 0.175 g
PEG 400 0.25 g
CP 0.075 g
Y-27632·2HCl 1.7 mg
DI H2O to 50 mL
Table 2
Working formulae of methylene blue and ROCK inhibitor Y-27632 comparator eyedrops.
Eyedrops Working formula
Methylene blue Methylene blue 87.7 mg
DI H2O to 5 mL
ROCK inhibitor Y-27632 Y-27632 16 mg
DI H2O to 5 mL
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ried out with methylene blue ﬁlm.
2.4. Transcorneal freezing of porcine eyes
Transcorneal freezing has been used as a therapeutic modality prior
to Y-27632 application in the formof eye drops (Koizumi et al., 2013). In
the experiments described here, to test if cryoprobe-treated eyeballs
achieved a better ingress of drug, transcorneal freezing was conducted
(Fig. 3) by gently touching the tip of a newly designed cryoprobe onto
the surface of freshly obtained porcine eyeballs for 3 s, which we have
shown to be optimal to produce reliable and reproducible areas of cor-
neal endothelial cell death. The cryoprobe tip is 3.4 mm in diameter
and reaches−50 °C via the internal expansion of a cryogen (medical
grade nitrous oxide), and is made of silver for heightened thermal con-
ductivity. Six of 12 eyeballs used for the experiment underwent
transcorneal freezing and six did not.
2.5. Formulation of eye drops
Eyedrops of equal concentration to themethylene blue and ROCK in-
hibitor Y-27632 ﬁlm were formulated to act as a control. The working
formulae of the eyedrops are detailed in Table 2. The concentration of
Y-27632 incorporated was designed to replicate the concentration
used previously, which is 10 mM (Koizumi et al., 2013).
2.6. Ocular delivery from applied formulations, in vitro
Freshly excised porcine eyeballs were placed, cornea uppermost, in a
6-well cell culture plate. Circular patches, 1 cm in diameter, were ex-
cised from the medicated (methylene blue or Y-27632) mucoadhesive
ﬁlms (n = 3) using a cork borer and applied to the corneas, which
had beenwetted beforehandwith 300 μL PBS, and a combination of cap-
illarity and ﬁlm deformability ensured contact with the cornea. Eye
drops of equal concentration were also applied to porcine eyeballs as a
comparator (n= 3 for Y-27632, n= 2 for methylene blue). To simulate
blinking and tearing, the eyes were periodically irrigated with 300 μL
isotonic PBS. Y-27632 eye drops were used based on the dosing proce-
dure reported by Koizumi et al. (2013), in which 50 μL of 10 mM Y-
27632 was applied six times a day. To limit dehydration the eyeballs
were placed in PBS, such that the solution reached half way up the eye
(not contacting the cornea). The set-up was covered with a plastic lid
to retainmoisture andwas incubated in awater bath at 37 °C overnight.
The eyes were periodically bathed with aliquots of PBS in an effort to
simulate tears (Chan et al., 2014).
After 24 h, ﬁlmswere carefully removed from the corneas using ﬁne
forceps and the corneal surface of eye-drop treated eyes were gently
wiped with cotton buds. Corneas were then excised from the eyes and
each was cut into small pieces before being comminuted to a ﬁne pow-
der using a mortar and pestle after being frozen in liquid nitrogen. The
powders were carefully recovered and extracted into water afterFig. 3. Thaw forming in themiddle of the eyeball, showing transcorneal freezing has taken
place.placing on a rotating blood tube mixer overnight. Tubes were then cen-
trifuged at 5750 rpm for 30 min, the supernatant decanted and evapo-
rated at 60 °C in an oven. The residue was reconstituted in 1 mL of
deionised H2O, prior to analysis by HPLC.
2.7. HPLC analysis of methylene blue and ROCK inhibitor Y-27632
The concentration of methylene blue and ROCK inhibitor Y-27632
released from each ﬁlm and extracted from each cornea was quantiﬁed
by reverse phase HPLC using an Agilent series 1100 HPLC system, ﬁtted
with a Phenomenex Kinetex 5μ C18 100 Å 150 × 4.6mmcolumn, eluted
with a mobile phase comprised of H2O:ACN (50:50 v/v) with 0.5% of
TFA. The ﬂow rate was 1mLmin−1. For methylene blue thewavelength
was 246 nm and the retention time 3.9 min; for Y-27632 the wave-
length was 270 nm and retention time was 1.5 min. Calibration curves
of methylene blue and ROCK inhibitor Y-27632 were constructed
using standard solutions over the concentration range of 1–
3.91 × 10−3 mM. The linearity of the curves was as follows: R2 =
0.9999 for methylene blue; 0.9997 for Y-27632.
2.8. Statistical analysis
All data were analyzed using an InStat 3 statistical package
(GraphPad Software Inc., San Diego, CA, U.S.A). Comparisons of concen-
tration released from formulations into native and cryoprobe-treated
corneas were determined using ANOVA (Analysis of variance) and
Kruskal-Wallis post-tests, where p b 0.05 was considered statistically
signiﬁcant.
3. Results and discussion
3.1. Film preparation
Initially, a blank ﬁlm (i.e. not loaded with any medication) was pro-
duced and was found to have good clarity, transparency and pliability,
with the entire ﬁlm weighing approximately 500 mg and having an av-
erage thickness of 0.1mmasdetermined using a digitalmicrometer. Re-
covery (ﬁlm mass/total mass of additives except water) was 98.3%.
Representative images of the ﬁlms loaded with methylene blue or
ROCK inhibitor Y-27632 are shown in Fig. 4(a) and (b), respectively.
The ﬁlms appeared optically clear and were approximately 0.1 mm
thick. Both ﬁlms were pliable, which is important as they are to ﬁt
well to the curved cornea. Also, it was encouraging to ﬁnd no evidence
of drug crystals in theﬁlms at the levels added. Crystalswould be poten-
tially damaging to the cornea and would lead to unpredictable drug re-
lease rates.
Homogeneity and recovery were determined by sampling 5 × 1 cm
diameter patches from across the ﬁlm, dissolving in water and assaying
for drug by HPLC – no statistically signiﬁcant differences were found
(not shown). The recovery of the methylene blue ﬁlm was 111.8%
while the recovery of the Y-27632 ﬁlm was higher at 129.3%. Stability
was determined by sampling the ﬁlm stored at room temperature
over an 8 week period and assaying, again with no statistically signiﬁ-
cant differences found. The recovery of the medicated ﬁlms was higher
than that of the blank ﬁlm probably because the drugs attract a hydra-
tion shell, resulting in a higher water content. In the case of Y-27632,
which was added as the hydrochloride salt, the positive charge would
Fig. 4. (a) Methylene blue ﬁlm. (b) ROCK inhibitor Y-27632 ﬁlm.
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that increasing the drying timedid not signiﬁcantly reduce the recovery.
The polymers hydroxyproplymethyl cellulose (HPMC), polyethylene
glycol 400 (PEG 400) and Carbopol 917 (CP) were used in the ﬁlm-
forming excipients described here. The suitability of a HPMC ﬁlm as a
drug vehicle considered several factors, such as the mechanical proper-
ties, the swelling of ﬁlms, and in vitro and in vivo bioadhesion evalua-
tions (Peh and Wong, 1999). Compared to SCMC (sodium
carboxymethyl cellulose) ﬁlm, another polymer, HPMC ﬁlms were
shown to possess a greater bioadhesive strength value in vivo, and
were reported to be tougher and more elastic. Consequently, we decid-
ed to use HPMC as our drug vehicle in this study. Moreover, PEG 400, a
commonly used solubilizer which exists in liquid form,was included for
its plasticizing properties, giving softness and pliability to the ﬁlms to
their ﬁtting to the curved corneas. In previous experiments, PEG of a
lower molecular weight (b300) had produced tough, brittle ﬁlms that
would not be suitable for ophthalmic applications (unpublished data).
Our use of PEG 400 is supported by the work of Llabot et al. (2007)
who revealed that its addition to ﬁlms enhancedmucoadhesion as com-
pared to the ﬁlm without it. This can be explained by the diffusion the-
ory of bioadhesion (Chickering and Mathiowitz, 1999) in which the
intra-chain polymeric interaction is reduced in the presence of plasti-
cizers, increasing the ﬂexibility of the chains. This would result in
strengthened mucoadhesive interactions by increasing the inter-pene-
tration and entanglement of bioadhesive polymer chains with mucin.
Carbopol is another polymer used to develop our polymeric ﬁlm. It is a
high molecular weight polymer containing a high content of carboxylic
groups (Rowe et al., 2012), which is believed to contribute to the
mucoadhesiveness of the ﬁlm (Chickering and Mathiowitz, 1999).
Carbopol plays an important role in increasing the softness, elasticity
and bioadhesive strength of polymeric ﬁlms (Lubrizol, 2015). Each of
the polymers used is an approved excipient. In conclusion, the combina-
tion of HPMC, PEG 400 and CP provided homogeneous, stable, soft, pli-
able and mucoadhesive ﬁlms, which are crucial properties of a viable
product.
3.2. Diffusional release
Diffusional release is the processwhereby drugmolecules spontane-
ously migrate from the polymeric system to the exterior of the polymer
and then into the releasemedium (Langer, 1990), which in our casewas
PBS to provide a basic model for tears. The diffusional release proﬁles of
loaded drug characterize the amount of drug released from the ﬁlm as a
function of time into a given receivingmedium. Low release is indicative
of low drug loading or interaction and extensive retention of loaded
drug within the ﬁlm matrix; whilst this can reduce the dose delivered,
it can also provide zero-order release. Zero-order kinetics is generally
desirable in drug delivery systems,where drug levels releasedwould re-
main constant throughout the delivery period (Ummadi et al., 2013).This is generally considered to be important in improving therapeutic
outcomes and patient compliance and it also reduces the frequency of
drug administration (Gokhale, 2014), which is discussed in Section
3.5. On the other hand, high release gives rise to ‘burst’ kinetics, and re-
ﬂects excess drug added and/or weak retentionwithin the polymerma-
trix – it is generally considered undesirable in drug delivery devices as it
would not provide sustained release; furthermore excess drug is often
present as crystals.
3.2.1. Methylene blue ﬁlm
The purpose of producing a ﬁlm containing methylene blue was to
provide a model solute which was visible to the naked eye and allowed
us to develop the ﬁlm production technique – it is however, also used
clinically as a photosensitizer (Tardivo et al., 2005). A diffusional release
proﬁle of methylene blue was constructed as cumulative mass and
moles released, normalized per amount of ﬁlm, hence, mass
(mg drug mg−1 of ﬁlm) and amount (μMol mg−1 of ﬁlm) released are
presented as a double-Y plot in Fig. 5; for further comparison purposes
the percentage released (%) is also shown in Fig. 7 over the timescale of
6 h to reﬂect an overnight application. The intensity of the blue colora-
tion of the receiving PBS solution visibly increased the longer the ﬁlm
was retained in the Eppendorf tube. From this observation it is deduced
that an increased concentration of methylene blue diffused into PBS so-
lutionwith increased contact time. Thiswas veriﬁed following quantita-
tive analysis by HPLC analysis as shown in Fig. 5, where the
concentration of methylene blue released from ﬁlm increased with in-
creased immersion time. Fig. 5 shows an initial linear, or 0-order, rela-
tionship between cumulative amount and mass within the ﬁrst
60min. The rate constant, as determined from the plot gradient, was de-
termined to be 0.0448 mg min−1. The steady state phase was followed
by a tailing off due to drug depletion. Methylene blue was detected in
the ﬁrst sample taken at 10 s as 0.22 μMol mg−1 (0.07 mg mg−1) and
at 6 h was 48.84 μMol mg−1 (15.62 mg mg−1).
3.2.2. ROCK inhibitor Y-27632 ﬁlm
Diffusional release proﬁles of ROCK inhibitor Y-27632 were con-
structed as cumulativemass (mgmg−1 of ﬁlm) (Fig. 6a) and percentage
released (%) (Fig. 6b). For further comparison purposes the percentage
released (%) is also shown in Fig. 7. Drug was detected in the ﬁrst sam-
ples taken at 10s (10 mg ﬁlm; 1.94 mg mg−1: 5.2 mg ﬁlm; 1 mgmg−1:
1.7 mg ﬁlm; 0.99 mg mg−1), with release increasing rapidly until it ap-
proaches equilibrium between 40 and 60 min (10 mg ﬁlm; approxi-
mately 11.5 mg mg−1: 5.2 mg ﬁlm; 9 mg mg−1: 1.7 mg ﬁlm;
2.5 mg mg−1). Thereafter, there was no major increase, and both
amount and mass are proportionate to each other. Fig. 6 shows the cu-
mulative concentration and mass of Y-27632 released over the 6 h test
period. It is immediately apparent that the release proﬁle for Y-27632
differed markedly to that of methylene blue, in that there was no
Fig. 5. Double Y-plot of methylene blue cumulative mass and μMol released over the timescale of 6 h, and normalized in terms of the mass of the ﬁlm sample (n = 3 ± SD).
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the ﬁrst 10 min.
The diffusional release of Y-27632 was replicated using three con-
centrations of Y-27632 ﬁlms; 10 mg, 5.2 mg and 1.7 mg. The difference
in concentrations has resulted in the difference in mass of Y-27632 re-
leased (Fig. 6a), so that the higher the concentration of Y-27632 within
the ﬁlm, the higher the mass of drug released. Interestingly, theFig. 6. (a) Cumulative drug release from thin ﬁlms loadedwith 1.7, 5.2 and 10mg ROCK inhibito
(b) percentage of drug released from thin ﬁlms loaded with 1.7, 5.2 and 10 mg ROCK inhibitordifference between the 10 mg ﬁlm and the 5.2 mg ﬁlm was not large
(the difference in mass was mostly kept within 2 mg mg−1). However,
the 10 mg ﬁlm showed a clearer burst release. Mass released from the
1.7mg ﬁlmwasmuch lower than the others where the highestmass re-
leased was only 2.8 mgmg−1, but the overall release pattern was simi-
lar to both 5 mg and 10 mg ﬁlms. Though concentrations varied, the
percentage releasedwas fairly similar (Fig. 6b). All three concentrationsr Y-27632 over 6 h and normalized in terms of themass of the ﬁlm sample (n= 3± SD);
Y-27632 over 6 h (n = 3 ± SD).
Fig. 7. Diffusional release proﬁles of methylene blue versus ROCK inhibitor Y-27632 in
percentage released (%) (n = 2 or 3 ± SD).
Fig. 8. Delivery of methylene blue to a cryoprobe-treated porcine cornea.
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maximum release ≥80%. As the release kinetics were greatest from the
10 mg ﬁlm, this was chosen to progress to the in vitro ocular delivery
experiment.
3.3. Comparison of methylene blue and ROCK inhibitor Y-27632 release
Fig. 7 shows that both methylene blue and ROCK inhibitor Y-27632
were released from respective ﬁlms up to approximately 90% after 6 h
- the pathways appear very different, although further work will be
needed to conﬁrm this. High release indicates low retention of drug in
the polymericﬁlms,which is due to swelling andwould be cost effective
by reducing wastage of drugs to a minimal level. Y-27632 was found to
be more weakly retained within the polymeric ﬁlm than methylene
blue, meaning it is more easily released, allowingmore Y-27632 to pen-
etrate the cornea; hence, a burst release from Y-27632 was observed. It
is worth noting that the release of Y-27632 depleted after 40 min (ap-
proximately 80% has been released), which could have the potential
beneﬁt of getting more drugs into the eyes rapidly. While methylene
blue displayed zero-order release kinetics over the 6 h timescale, Y-
27632 showed mixed-order release, reaching equilibrium within
50 min. It is deduced that this is due to the lack of interaction of Y-
27632 with the ﬁlm polymers. It is assumed that methylene blue is
able to form stronger bonds with the polymers (Chickering and
Mathiowitz, 1999) and that this results inmore entrapment in the poly-
meric ﬁlm. It is also hypothesized that the burst release of Y-27632 was
facilitated by its low molecular size and the presence of the charge,
which the recovery data (Section 3.1) showed attracted more water.
This, in turn, accelerated release of the hydrated complex into the aque-
ous receiving medium. It should also be borne in mind that such rapid
release may be a concern if it gives rise to toxic levels in vivo (Shively
et al., 1995; Jeong et al., 2000).
On a side note, methylene blue is used clinically as a visual guide
during surgery or endoscopy (Tardivo et al., 2005), and is also a thera-
peutic agent for various conditions, including ifoasfamide-induced en-
cephalopathy (Patel, 2006) and methemoglobinemia (Sikka et al.,
2011) - the current delivery data of methylene blue using the thin
ﬁlm has potential relevance in such procedures.
3.4. Transcorneal freezing
As mentioned, transcorneal freezing achieved by touching the cor-
neal surface with a cold probe can cause corneal endothelial cell
death, either by forming intracellular ice that is lethal to the cell or by
the formation of extracellular ice, which will create an osmoticimbalance leading to an increase in intracellular electrolytes and the
collapse of cellular membranes. It was previously reported that corneal
endothelial cells are expected to proliferate at the frozen wound sites
after cryotherapy (Buco et al., 1978; Staatz and Van Horn, 1980), and
potentially the application of Y-27632 eye drops enhances this recovery
(Koizumi et al., 2013). Fig. 8 shows a picture taken upon the excision of a
cryoprobe-treated cornea to which a methylene blue ﬁlm had been ap-
plied. From this observation it was evident that penetration of methy-
lene blue occurred predominantly at the centre of the cornea where
transcorneal freezing took place.3.5. Corneal penetration
As the corneal endothelium is the target site for Y-27632 following
its surface application, it was important to ensure that the drug is pen-
etrating towards the back of cornea to reach endothelial tissue. Since
Y-27632 is colourless, methylene blue ﬁlm was used as a model. Fig. 9
shows a schematic diagram of the cornea throughout its full thickness
alongside a lateral view of the cornea from a cryoprobe-treated eyeball
under a microscope. The endothelium is stained blue, depicting that
drug is penetrating well through the cornea from the epithelial surface
where the patch had been positioned on eye.3.6. Ocular drug delivery
Koizumi et al. (2013) reported some patients with FECD who were
successfully treatedwith ROCK inhibitor Y-27632 eye drops subsequent
to transcorneal freezing to remove diseased anddamaged corneal endo-
thelial cells. While the reported results are encouraging, the eye drop
application was repeated six times a day for 7 days. Eye drops have
long been used to treat ocular pathology and injury, however, it is wide-
ly appreciated that upon application an eye drop dose is rapidly elimi-
nated by dilution and washing out by tears and nasolacrimal drainage
mechanisms. More often than not the instilled dose that enters ocular
tissue is less than 1% (Morrison, 2015). Furthermore, ROCK inhibition
is known to have a hypotensive effect and vascular resistance, which
would result in potential adverse effects on unwanted systemic expo-
sure (Hahmann and Schroeter, 2010). Another reported adverse effect
of ROCK inhibitor eye drop application is ocular hyperemia because
ROCK inhibitors are vasodilators, and this has been evident in ongoing
clinical trials (Tanihara et al., 2013; Zhang et al., 2012). Drug wasted
via eye drop delivery also represents sub-optimal drug therapy for the
patient. Hence, the potential beneﬁt of the development of a
mucoadhesive ﬁlm that is capable of sustained delivery of higher
doses, speciﬁcally targeting the corneal endothelium.
Fig. 9. Schematic diagram of the cornea layers and a microscopy lateral view of the cornea from a cryoprobe-treated porcine eyeball.
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Run off of the dose applied as eyedrops is a well-known aspect of
this mode of delivery and was vividly depicted in this work involving
methylene blue (Fig. 10). In the experimental setup used, it was a
challenge to accurately mimic the washing out action of tears and
blinking. However, during the experiment the porcine eyeballs
were periodically irrigated with 300 μL PBS in an effort to crudely
simulate washing out. This revealed that methylene blue was visibly
washed away on wetting as the intensity of the blueness decreased
(as shown in Fig. 10). Methylene blue in ﬁlms, on the other hand,
remained and the drug did not drain away appreciably even after ir-
rigation. This indicates a major advantage delivery via mucoadhesive
ﬁlms over eyedrops, whereby drug run off and washing away by
tears are reduced, with the drug being retained at point of
application.3.8. Delivery of methylene blue to the cornea
The delivery ofmethyleneblue fromﬁlmand eye drops of equal con-
centrations to untreated in vitro porcine corneas and cryoprobe-treated
porcine corneas (n = 2 or 3; ±SD) is shown in Fig. 11. It can be seen
that methylene blue delivered from the thin ﬁlm (0.072 mMol in un-
treated cornea and 0.081 mMol in cryoprobe-treated cornea) was sig-
niﬁcantly greater than the amount delivered from liquid eye drops
(0.046mMol in untreated cornea and 0.066mMol in cryoprobe-treated
cornea) for both untreated (p b 0.01) and cryoprobe-treated corneas
(p b 0.05). The ﬁlm delivered signiﬁcantly more methylene blue to the
cryoprobe-treated corneas as compared to native corneas (p b 0.05)
and this was even more apparent for the eye drop-delivered agent
(p b 0.0001). This is probably a consequence of the cryoprobe-treated
corneas being more “leaky” owing to a modulation or disruption the
cell and matrix components of the cornea cause by tissue freezing,
which allows more drug to penetrate.Fig. 10. Porcine eyeballs treated with ﬁlm patch (upper) or equivalent ‘eyedrop’ solution (lo
amounts of MB immediately following application. Lower right shows that upon irrigation fu
shows no detectable wash out of MB from applied ﬁlms following irrigation (3 determinations3.9. Delivery of ROCK inhibitor Y-27632 to the cornea
The corneal delivery of ROCK inhibitor Y-27632 from ﬁlms and eye
drops of equal concentration into native unfrozen porcine corneas and
cryoprobe-treated porcine corneas (n = 2 or 3 ± SD) are shown in
Fig. 12. It can be seen that for cryoprobe-treated corneas, the rapid dif-
fusional release (Section 3.2.2) wasmanifested in the delivery of almost
3 times more Y-27632 (0.52 mMol) when compared to delivery via the
equivalent eye drop solution (0.177 mMol) (p b 0.01). For native cor-
neas, Y-27632 delivered from the thin ﬁlmwas greater than from liquid
eye drops, although this was not statistically signiﬁcant (p N 0.05). The
ﬁlms delivered signiﬁcantly more Y-27632 to the cryoprobe-treated
corneas (0.52 mMol) as compared to native corneas (0.23 mMol)
(p b 0.01). The eye drops appeared to deliver more Y-27632 across the
cryoprobe-treated corneas, although thiswasnot statistically signiﬁcant
(p N 0.05). Prior to the development of a 10 mM Y-27632 ﬁlm, a lower
concentration Y-27632 ﬁlm was produced (containing 10 mg of Y-
27632). The delivery onto the cryoprobe-treated corneas of this was
much lower (0.083 mMol) due to the lower concentration of the ﬁlm
(n = 3 ± SD).
Y-27632 has been reported to have no direct toxicity or signiﬁcant
effects on cell proliferation (Honjo et al., 2007), and a protective effect
was observed for mouse motoneurons in a cytotoxicity assay following
Y-27632 treatment (Günther et al., 2014). A clinical study involving an-
other ROCK inhibitor, SNJ-1656 proved that it is a safe topical agent and
effective in reducing intraocular pressure in the eyes of human volun-
teers (Tanihara et al., 2008).
4. Conclusions
This study has compared drug delivery to the cornea achieved via
eye drops or release frommucoadhesive thin ﬁlms. Initially, methylene
blue as a model agent, followed by 10 mMol of selective ROCK inhibitor
Y-27632, which is a drug used to treat vision loss caused by corneal en-
dothelial dysfunction as would occur in FECD and/or bullouswer) immediately after application (left). Lower left clearly shows run off of signiﬁcant
rther MB is washed away from the eyeball dosed with eyedrops. In contrast, upper right
).
Fig. 11. The corneal delivery of methylene blue from ﬁlm and ‘eye drops’ of equal
concentration across native porcine corneas and cryoprobe-treated porcine corneas
(n = 2 or 3 ± SD).
263W. Chan et al. / European Journal of Pharmaceutical Sciences 91 (2016) 256–264keratopathy. Themajor conclusions are: (1) drug delivery to the cornea
via thin mucoadhesive ﬁlms is a superior alternative to eye drop deliv-
ery because (at equal concentrations) signiﬁcantly higher concentra-
tions of Y-27632 were observed in the cornea after delivery from thin
ﬁlms compared to delivery via eye drops. This suggests the delivery of
ROCK inhibitor from thin mucoadhesive ﬁlms may produce better clin-
ical results compared to eye drops. (2) thin mucoadhesive ﬁlms have
advantages over eye drops in that dose is well retained at point of appli-
cation on thin ﬁlm application, whereas eye drops are easily washed
away by tearing and blinking of eyes. (3) thin ﬁlms result in a 3-times
higher delivery of Y-27632 over and above that achieved by eye drop
delivery on cryoprobed-treated corneas. This suggests that targeted de-
livery of Y-27632 to the cryoprobe-treated, freeze-damaged tissue at
the front of the cornea allows the ROCK inhibitor to penetrate more
readily into and across cornea. Thus, a combination of transcorneal
freezing and topical application of ROCK inhibitor via thin ﬁlms is a po-
tential non-invasive approach to deliver relatively higher concentra-
tions of drugs into the corneal endothelium. In summary, ﬁndings
from this study support the further development of mucoadhesiveFig. 12. The ocular delivery of ROCK inhibitor Y-27632 from ﬁlm and eyedrops of equal
concentration across native porcine corneas and cryoprobe-treated porcine corneas
(n = 3 ± SD).thin ﬁlms as a modality for the targeted delivery of ROCK inhibitors to
the cornea (with or without transcorneal freezing) to treat corneal en-
dothelial dysfunction. The approach also has wider potential in the
use of thinmucoadhesive ﬁlms as an alternative to eye drop application
in other scenarios, and could possibly apply to other ocular diseases by
incorporating other disease-target drugs.References
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